| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1339 | |
| Phytochemical name or plant extracts | Daidzin | |
| PMID | 15492830 | |
| Literature evidence | Taken together, our results suggest that dietary soy isoflavones inhibit adhesion and motility of highly invasive breast cancer cells by distinct signaling pathways. | |
| IUPAC name | 3-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Flavanoid | |
| Source of phytochemicals or plant Extracts | Glycine max | |
| Geographical availability | Amur, China North-Central, China South-Central, China Southeast, Hainan, Inner Mongolia, Japan, Khabarovsk, Korea, Laos, Manchuria, Nansei-shoto, Primorye, Qinghai, Taiwan, Thailand, Tibet, Vietnam, Xinjiang | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | ER | |
| Gene or Protein evidence | Furthermore, in drug interaction studies daidzin-rich isoflavone extracts antagonized tamoxifen, an ER inhibitor. | |
| Target pathways | NF-kappaB/AP-1-dependent and -independent pathways | |
| IC50 | 50 µg/mL against ZR-75-1 | |
| Potency | NA | |
| Cell line/ mice model | ZR-75-1, MDA-MB-231, MCF-7 | |
| Additional information | Inhibits constitutively active NF-kappaB and AP-1 and suppresses secretion of uPA from breast cancer cells, reduces motility of MDA-MB-231 cells. Enhances the acetylcholinesterase (AChE) activity of the rat neuronal cell line PC12 at concentrations as low as 0.08 muM by binding to the estrogen receptor (ER). 2. significantly decreases 8-hydroxydeoxyguanosine content and increased superoxide dismutase level in normal rats and decreased malondialdehyde concentrations in ovariectomized rats | |
| PubChem ID | 107971 | |
| Additional PMIDs | 19003112 18313242 12670155 27043076 15492830 8910911 4426188 2749004 17142977 26658676 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60450240-2 | |
| Safety | NA |